Coverage dated December 19, 2021 to December 20, 2021
Biogen halves price of Alzheimer's drug after criticism
Headline from Foxla
The drugmaker said Monday that it will cut the wholesale acquisition cost of the drug by about 50% next month. That means the annual cost for a person of average weight will amount to $28,200.
Foxla's own description from its feed. We collect headlines and these descriptions, not full articles; read the original reporting below.
Biogen on Monday cut in half the price of its Alzheimer's drug Aduhlem in an effort to boost lackluster sales that stemmed in part from controversy over its price.
Biogen is slashing the price of its Alzheimer's treatment months after the drug debuted to widespread criticism for an initial cost that can reach $56,000 annually.
The drugmaker said Monday that it will cut the wholesale acquisition cost of the drug by about 50% next month. That means the annual cost for a person of average weight will amount to $28,200.
Biogen announced the Alzheimer's drug Aduhelm will now cost patients $28,200 per year after doctors were hesitant prescribing the treatment due to costs.
The price cut will reduce the average annual cost of treatment to $28,200 a patient from the $56,000 the company set when the drug was approved in June, Biogen said Monday.
Biogen is slashing the price of its Alzheimer's treatment in half months after it debuted to widespread criticism for an initial cost that could reach $56,000 annually.
Identical headlines usually mean shared wire copy. They are counted as separate articles but are not independent confirmation.
Biogen halves price of Alzheimer's drug after criticism | Since Then
